MX361230B - Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. - Google Patents
Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas.Info
- Publication number
- MX361230B MX361230B MX2013008606A MX2013008606A MX361230B MX 361230 B MX361230 B MX 361230B MX 2013008606 A MX2013008606 A MX 2013008606A MX 2013008606 A MX2013008606 A MX 2013008606A MX 361230 B MX361230 B MX 361230B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- cyaa
- immune responses
- induce
- therapeutic
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 230000028993 immune response Effects 0.000 title abstract 4
- 230000000069 prophylactic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000001575 pathological effect Effects 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición que comprende un primer grupo de epítopes y un segundo grupo de epítopes, para usarse en el tratamiento inmunoterapéutico de una primera condición patológica y profilaxis de una segunda condición patológica en un huésped mamífero, en donde los grupos de epítopes son de la proteína E6 o de la proteína E7 de un tipo de HPV oncogénico seleccionado del grupo que consiste en HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 Y HPV58, en donde el primer grupo de epítopes está contenido en un polipéptido y el segundo grupo de epítopes está contenido en el mismo polipéptido y dicho polipéptido es llevado por un vector o en donde el primer grupo de epítopes está contenido en un polipéptido diferente y dichos polipéptidos son llevados por el mismo vector o son llevados por vectores separados, y en donde el(los) vectores(es) es(son) una proteína CyaA, o un fragmento de la misma, en donde dicho primer grupo de epítopes no es suficiente para obtener profilaxis contra la segunda condición patológica, en donde el primer grupo de epítopes produce un respuesta inmune de células T contra el primer grupo de epítopes después de administrar dicha composición proporcionando así un tratamiento inmunoterapéutico contra dicha primera condición patológica asociada con dicho primer grupo de epítopes, y en donde, después de administrar dicha composición, el segundo grupo de epítopes produce una respuesta inmune de memoria de células T contra el segundo grupo de epítopes después de administrar dicha composicón, proporcionando así profilaxis contra dicha segunda condición patológica asociada con dicho segundo grupo de epítope.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305069A EP2478915A1 (en) | 2011-01-24 | 2011-01-24 | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
PCT/EP2012/051027 WO2012101112A1 (en) | 2011-01-24 | 2012-01-24 | Cyaa-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013008606A MX2013008606A (es) | 2013-12-09 |
MX361230B true MX361230B (es) | 2018-11-30 |
Family
ID=43971828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013008606A MX361230B (es) | 2011-01-24 | 2012-01-24 | Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9902947B2 (es) |
EP (2) | EP2478915A1 (es) |
JP (2) | JP6014604B2 (es) |
KR (1) | KR101975610B1 (es) |
CN (1) | CN103476424A (es) |
AU (1) | AU2012210612B2 (es) |
BR (1) | BR112013018742A2 (es) |
CA (1) | CA2825470A1 (es) |
ES (1) | ES2748381T3 (es) |
MX (1) | MX361230B (es) |
RU (1) | RU2668795C2 (es) |
WO (1) | WO2012101112A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2690172A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses |
EP2689786A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
KR20230076867A (ko) | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
US10975442B2 (en) | 2014-12-19 | 2021-04-13 | Massachusetts Institute Of Technology | Molecular biomarkers for cancer immunotherapy |
WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
EP3037103A1 (en) * | 2014-12-23 | 2016-06-29 | Genticel | Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV |
MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
US10313363B2 (en) * | 2015-11-24 | 2019-06-04 | Bank Of America Corporation | Proactive intrusion protection system |
WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0637335B1 (en) | 1992-04-21 | 2007-07-25 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
PT1188446E (pt) | 2000-09-15 | 2009-11-10 | Pasteur Institut | Vectores proteinácios para a distribuição da molécula a células que expressam cd11b |
EP1689772A2 (en) * | 2003-10-14 | 2006-08-16 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
WO2005053738A1 (en) * | 2003-11-21 | 2005-06-16 | Institut Pasteur | Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
PL1576967T3 (pl) | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
US9486524B2 (en) * | 2006-09-01 | 2016-11-08 | Genticel | Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
EP1894941A1 (en) * | 2006-09-01 | 2008-03-05 | Institut Pasteur | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens |
EP2134359A4 (en) * | 2007-02-23 | 2010-06-16 | Penn State Res Found | USE OF A NONVIRULENT BORDETELLA MUTANT AS LIVING VACCINE VECTOR |
-
2011
- 2011-01-24 EP EP11305069A patent/EP2478915A1/en not_active Withdrawn
-
2012
- 2012-01-24 BR BR112013018742A patent/BR112013018742A2/pt not_active Application Discontinuation
- 2012-01-24 CN CN2012800148671A patent/CN103476424A/zh active Pending
- 2012-01-24 RU RU2013136148A patent/RU2668795C2/ru not_active IP Right Cessation
- 2012-01-24 CA CA2825470A patent/CA2825470A1/en not_active Abandoned
- 2012-01-24 ES ES12701110T patent/ES2748381T3/es active Active
- 2012-01-24 JP JP2013549843A patent/JP6014604B2/ja not_active Expired - Fee Related
- 2012-01-24 AU AU2012210612A patent/AU2012210612B2/en not_active Ceased
- 2012-01-24 EP EP12701110.4A patent/EP2667890B1/en active Active
- 2012-01-24 WO PCT/EP2012/051027 patent/WO2012101112A1/en active Application Filing
- 2012-01-24 MX MX2013008606A patent/MX361230B/es active IP Right Grant
- 2012-01-24 KR KR1020137022115A patent/KR101975610B1/ko active IP Right Grant
- 2012-01-24 US US13/981,250 patent/US9902947B2/en not_active Expired - Fee Related
-
2016
- 2016-06-01 JP JP2016110076A patent/JP2016208979A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112013018742A2 (pt) | 2017-11-14 |
AU2012210612B2 (en) | 2016-07-14 |
ES2748381T3 (es) | 2020-03-16 |
JP2016208979A (ja) | 2016-12-15 |
US9902947B2 (en) | 2018-02-27 |
MX2013008606A (es) | 2013-12-09 |
AU2012210612A1 (en) | 2013-05-02 |
EP2478915A1 (en) | 2012-07-25 |
CN103476424A (zh) | 2013-12-25 |
CA2825470A1 (en) | 2012-08-02 |
JP6014604B2 (ja) | 2016-10-26 |
EP2667890B1 (en) | 2019-07-03 |
JP2014506562A (ja) | 2014-03-17 |
KR20140034147A (ko) | 2014-03-19 |
KR101975610B1 (ko) | 2019-05-07 |
US20140037670A1 (en) | 2014-02-06 |
EP2667890A1 (en) | 2013-12-04 |
WO2012101112A1 (en) | 2012-08-02 |
RU2013136148A (ru) | 2015-03-10 |
RU2668795C2 (ru) | 2018-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX361230B (es) | Polipéptido(s) transportado(s) por cyaa y uso para inducir respuestas inmunes tanto terapéuticas como profilácticas. | |
MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
MX354717B (es) | Moleculas de union novedosas con actividad antitumoral. | |
MX2020011781A (es) | Formulacion arn para inmunoterapia. | |
MX2021003370A (es) | Estado de ayuno como tratamiento dietetico de la diabetes. | |
NZ627078A (en) | Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy | |
NZ628449A (en) | Neisseria meningitidis compositions and methods thereof | |
EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
EP4218810A3 (en) | Multivalent meditopes, meditope-binding antibodies and uses thereof | |
MD20140104A2 (ro) | Polipeptide care se leagă de CX3CR1 | |
WO2012050874A3 (en) | Targeting heme for the treatment of immune mediated inflammatory diseases | |
IN2012DN06309A (es) | ||
WO2013188627A3 (en) | Cationic lipid vaccine compositions and methods of use | |
WO2017096327A3 (en) | Compositions and methods for reducing immune responses against chimeric antigen receptors | |
IN2014CN04071A (es) | ||
BR112014019328A8 (pt) | Perfil de fenótipo de células progenitoras retinais humanas | |
AU2014225575A8 (en) | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same | |
PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
WO2016023898A3 (en) | Intracellular antigen binding | |
MX2015008653A (es) | Anticuerpo especifico contra e. coli mdr. | |
WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
NZ631639A (en) | Methods and compositions for treating and diagnosing acute myocardial infarction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |